Search Results
Aug 26, 2026, 05:29 ET SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'
biopharmaceutical company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high
More news about: SK Biopharmaceuticals. Co., Ltd.
Aug 26, 2026, 02:36 ET Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
expected in 2H 2026. It is designed to offer an easy-to-use, once-daily oral treatment without the need for titration and a low incidence of burdensome CNS side effects.The agreement pairs Biohaven's innovative, wholly owned Kv7 platform with the proven epilepsy commercial
More news about: Biohaven Ltd.
Aug 25, 2026, 13:44 ET More than 25 national and international partners join Connected Nation's attempt to set a GUINNESS WORLD RECORDS™ title to expand digital skills worldwide
United States. Participants can watch for free from home, work, or a host site. Though they span six continents and a wide range of specialties, each of CN's partner organizations shares one goal: making digital skills accessible to advance economic and quality-of-life opportunities.The following
More news about: Connected Nation
Aug 25, 2026, 10:31 ET Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
within hours without requiring intensive patient monitoring. LPCN 1154 has shown clinically meaningful tolerability with minimal central nervous system (CNS) depressant effects and avoids the dissociative or hallucinogenic risks associated with psychedelic-based therapies, making it a promising option for
More news about: DelveInsight Business Research, LLP
Aug 25, 2026, 08:06 ET Cellenkos Receives FDA Fast Track Designation for CK0803 in Amyotrophic Lateral Sclerosis (ALS)
T-cell number and/or suppressive function that allows peripheral Th1/Th17 effector cells to infiltrate and amplify CNS injury.Because CK0803 was engineered to traffic toward inflamed CNS tissue via the CXCR3/CXCL10 and CD11a(LFA-1)/ICAM-1 axes — rather than toward a disease-specific antigen — the
More news about: Cellenkos, Inc.
Aug 24, 2026, 07:05 ET REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Aug 24, 2026, 03:01 ET ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
Differentiated CNS PlatformIn particular, ImmunoForge has fused its proprietary long-acting technology, ELP, with the LMT platform to implement BBB penetration and one-month sustained release in a single structure. This is expected to enable applications in various areas, including CNS-targeted
More news about: ImmunoForge Co., Ltd.
Aug 24, 2026, 01:21 ET GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
barrier (BBB) into the central nervous system (CNS). This approach aims to manage symptoms associated with CNS damage, including cognitive decline. Approximately 70% of all Hunter syndrome patients suffer from severe forms of the disease accompanied by CNS impairment.About GC BiopharmaGC
More news about: GC Biopharma
Aug 20, 2026, 12:26 ET The Multiple Sclerosis Association of America (MSAA) Recognizes Ten-Year Milestone of Online Support Platform, My MSAA Community
Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Aug 20, 2026, 07:00 ET Corero Network Security Launches AI-Augmented Cloud-Assist for SmartWall ONE™
(AIM: CNS)
More news about: Corero Network Security
Aug 20, 2026, 06:45 ET Cumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chez les personnes atteintes de sclérose latérale amyotrophique (SLA) et de dégénérescence fronto-temporale (DFT)
universitaire de neurologie du Trinity College de Dublin, chercheuse principale de l'étude PRECISIONALS et chercheuse principale de l'étude CNS-102. « L'étude CNS-102 montre qu'une plateforme à domicile combinant l'EEG et une évaluation cognitive multidomaine peut être bien tolérée, voire appréciée, par
More news about: Cumulus Neuroscience
Aug 20, 2026, 02:14 ET Cumulus Neuroscience gibt die Veröffentlichung eines Artikels in der Fachzeitschrift „Scientific Reports" bekannt, der belegt, dass die NeuLogiq®-Plattform für die multimodale kognitive Beurteilung von Menschen mit ALS und FTD zu Hause geeignet und einsetzbar ist
MD, Leiterin der Akademischen Abteilung für Neurologie am Trinity College Dublin, leitende Forscherin von PRECISIONALS und Hauptforscherin von CNS-102. „CNS-102 zeigt, dass eine Plattform für den Heimgebrauch, die EEG mit einer kognitiven Mehrbereichsuntersuchung kombiniert, von Menschen mit erheblichen
More news about: Cumulus Neuroscience
Aug 19, 2026, 09:41 ET Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
CAMBRIDGE, Mass., Aug. 19, 2026 /PRNewswire/ -- Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced that Phase
More news about: Sensorium Therapeutics
Aug 18, 2026, 12:06 ET Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Hardiman, MD, Head of the Academic Unit of Neurology at Trinity College Dublin, Lead Investigator of PRECISIONALS and Principal Investigator of CNS-102. "What CNS-102 shows is that a home-based platform combining EEG with multi-domain cognitive assessment can be tolerated, and even welcomed, by people living
More news about: Cumulus Neuroscience
Aug 18, 2026, 11:44 ET Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
Hardiman, MD, Head of the Academic Unit of Neurology at Trinity College Dublin, Lead Investigator of PRECISIONALS and Principal Investigator of CNS-102. "What CNS-102 shows is that a home-based platform combining EEG with multi-domain cognitive assessment can be tolerated, and even welcomed, by people living
More news about: Cumulus Neuroscience
Aug 18, 2026, 11:24 ET Vertical Data Appoints Chris Downs as Interim Chief Financial Officer
national securities exchange."Downs most recently served for approximately six years (November 2019-March 2026) as Chief Financial Officer of CNS Pharmaceuticals, Inc., where he led the company's financings, including follow-on, PIPE, at-the-market and equity line transactions, and directed its
More news about: Vertical Data Inc
Aug 18, 2026, 09:00 ET J.P. Morgan Life Sciences Private Capital Welcomes Bruce N. Rogers, Ph.D. as Venture Partner
planning. Before his tenure at Morphic, he served as Head of Neuro-Opportunities at Pfizer, leading innovative initiatives for central nervous system (CNS) disorders, including direct brain delivery of protein therapeutics for Parkinson's disease and oncology-oriented approaches. He also spent 16 years
More news about: J.P. Morgan Asset Management
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
Brand Communications, LIB Therapeutics, Inc.Cardiopulmonary: Michelle Gallant, Senior Director of U.S. Marketing, LiquidiaCNS: Patti Russo, Worldwide VP, Immunology Global Commercial Strategy, Bristol Myers SquibbDermatology: Brittany Mathes, Senior Director,
More news about: PM360
Aug 17, 2026, 11:00 ET Cohen & Steers and DLC Acquire Royal Plaza Grocery Shopping Center in Front Royal, Virginia
NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that the Cohen & Steers Real Estate Opportunities Fund (REOF) has acquired Royal Plaza, a grocery-anchored center in Front Royal, Va.,
More news about: Cohen & Steers, Inc.
Aug 17, 2026, 09:00 ET Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia
in 2021 and is headquartered in Worcester, Mass. Leal's lead programs address the critical intersection between CNS and metabolic disorders. The Leal team has particular expertise in CNS therapeutic development, as well as leveraging human genetics, functional genomics and biomarker analyses to support
More news about: Leal Therapeutics
Aug 17, 2026, 08:00 ET 28bio Launches CNS-3D Plasticity Organoids to Assess Drug Effects on Human Learning and Memory
"That is what allows the same set of functional endpoints to inform programs across multiple CNS indications."CNS-3D Plasticity Organoids and cognitive biomarker assays are now available through 28bio CNS-3D Services.About 28bio28bio is a neurotechnology company engineering
More news about: 28bio
Aug 14, 2026, 16:05 ET Cohen & Steers Announces Changes to Realty Indexes
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as
More news about: Cohen & Steers, Inc.
Aug 14, 2026, 02:19 ET LG to Unveil Its Next-Gen Humanoid Robot, Built on NVIDIA Isaac GR00T
production facilities, homes, and commercial spaces.The collaboration also includes technical work to build a robot data factory powered by LG CNS PhysicalWorks, LG's robot data platform. PhysicalWorks will be developed to support an on-site physical AI data factory for continuous data collection,
More news about: LG Corp.
Aug 13, 2026, 22:30 ET LG to Unveil Its Next-Gen Humanoid Robot, Built on NVIDIA Isaac GR00T
production facilities, homes, and commercial spaces.The collaboration also includes technical work to build a robot data factory powered by LG CNS PhysicalWorks, LG's robot data platform. PhysicalWorks will be developed to support an on-site physical AI data factory for continuous data collection,
More news about: LG Corp.
Aug 13, 2026, 08:15 ET Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
unmet medical needs using its patented iSPERSE™ technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis
More news about: Pulmatrix Inc.